Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to support Yayasan Seri Negara’s (YSN) Ihya Ramadhan 2022 programme through a monetary donation to help those in need.
Dato’ Seri Mazlan Lazim, Patron of Yayasan Seri Negara and Encik Azri Azerai, Executive Director of Malaysian Genomics Resource Centre [L-R]
The Ihya Ramadhan 2022 programme will be held in several locations throughout the country and involves the breaking of fast and the giving of monetary aid to orphans and the underprivileged.
Encik Azri Azerai, Executive Director of Malaysian Genomics, said, “We are happy and honoured to be able to assist YSN in their Ihya Ramadhan 2022 programme. Every little bit helps, and we want to do our part in easing the burden of those in need such as orphans and the underprivileged.”
Malaysian Genomics’ cash aid will be distributed to orphans and the underprivileged at the Shah Alam district police headquarters during the Ihya Ramadhan 2022 programme held at the location on 27 April 2022 at 6pm.
Malaysian Genomics Resource Centre Berhad: http://www.mgrc.com.my/ Malaysian Genomics Resource Centre Berhad: 0155 / [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK]
Malaysian Genomics Resource Centre Berhad (“Malaysian Genomics” or “the Group”), a leading genomics and biopharmaceutical specialist, was recently awarded a COVID-19 surveillance contract by the Institute for Medical Research (“IMR”), the biomedical research arm of the Ministry of Health (“MOH”). Malaysian Genomics is one of the private laboratories that IMR has engaged to outsource genome surveillance of SARS-CoV2.
Dato’ Alvin Nesakumar, Executive Director of Malaysian Genomics Resource Centre Berhad
Dato’ Alvin Nesakumar, Executive Director of Malaysian Genomics, said, “We are pleased to support IMR and MOH in this important effort to monitor the evolution of the COVID-19 virus, its variants and sub-variants. With our expertise and knowledge in genomics and bioinformatics, we can help IMR track and trace the virus for any variants of concern that the Government needs to be informed of as well as prepare for.”
Malaysian Genomics, whose cell laboratory is the only privately-owned BioSafety Level 2 (“BSL-2”) facility in Malaysia with the Current Good Manufacturing Practice (“cGMP”) certification, is moving towards becoming a premier healthcare provider through the production of CAR T-cells for cancer immunotherapy for solid cancers, as well as other cell engineering services. BSL-2 and cGMP certifications indicate that a laboratory facility has stringent measures for biocontainment standards and ultra-pure laboratory environments to safely work on human cells.
The Group is also ISO 9001:2015, ISO 15189:2014 and ISO 17025:2017 certified under the Integrated Management System.
Malaysian Genomics Resource Centre Berhad: http://www.mgrc.com.my/
